Neuroone Medical Technologie (NMTC) — Who's Buying and Selling (13F, Q2 2026)

NMTC ranks #7896 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

25 institutions disclose a position in NMTC, but none treat it as a major bet — even Perkins Capital Management Inc, its most concentrated holder, allocates just 0.6% of its own portfolio to it.

NMTC is up 3.7% today, and institutions have been net buyers of $6.2M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

NMTC reported a net loss of $7.4M over the trailing twelve months.

• Not yet profitable — net loss of $7.4M over the trailing twelve months
• Revenue grew 42.8% year over year
• Net income declined year over year, from -$5.3M to -$7.4M
• Operating cash flow was negative, using $2.8M in cash
• Current ratio of 4.44x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.53x equity — within a conventional range